Pfizer Heritage

BROUGHT TO YOU BY PFIZER: A GLOBAL LEADER IN ONCOLOGY THERAPY AND BIOSIMILAR DEVELOPMENT1-5

HELPING TO TRANSFORM CANCER CARE BY CREATING BREAKTHROUGH AND VALUE1,5

Pfizer develops innovative oncology therapies that aim to change patients’ lives2,6,7

- Pfizer currently has a number of approved oncology medicines while also having a significant number of potential approvals in clinical development2

- Pfizer also has numerous sterile injectable chemotherapies7

- Committed to the future, with a robust pipeline of novel cancer medicines that include biologics, small molecules, immunotherapies and biosimilars.2,6,7

Pfizer is a leading provider of oncology biosimilars2-8

Pfizer currently has a broad oncology biosimilar portfolio in the market1-5,7,8 Over 10 years of global experience with oncology biosimilars6

A global leader in the development and production of biologic medicines9-11

  • Over 30 years of experience providing high-quality biologic medicines- now to over 175 countries9,10
  • Pfizer implements a global supply network to provide flexible solutions across the full manufacturing and supply chain11

 

 

References:

  1. ZIRABEV® (bevacizumab) summary of product characteristics.
  2. Data on file. Pfizer oncology strategy and pipeline.
  3. European Medicines Agency. RETACRIT® (epoetin). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_.... Updated July 2011.  Accessed March 2021.
  4. European Medicines Agency. TRAZIMERA® (trastuzumab). https://www.ema.europa.eu/en/medicines/human/EPAR/trazimera. Updated May 8, 2019. Accessed March 2021.
  5. European Medicines Agency. NIVESTIM® (filgrastim). https://www.ema.europa.eu/en/medicines/human/EPAR/nivestim. Updated April 6, 2019. Accessed March 2021.
  6. Data on file. Oncology at Pfizer Narrative. Pfizer Inc., New York, NY. 2018.
  7. Pfizer Inc. Product pipeline. https://www.pfizer.com/science/drug-product-pipeline. Accessed March 2021.
  8. Pfizer RUXIENCE® (rituximab) Summary of Product Characteristics.
  9. Data on file. Certification of biosimilar claims. Pfizer Inc., New York, NY. 2016.
  10. Data on file. Pfizer global supply: overview. Pfizer Inc., New York, NY. 2018.
  11. Pfizer breaks ground on new biologics clinical manufacturing facility in Andover, Massachusetts [press release]. New York, NY: Pfizer Inc.; June 16, 2016.
     
PP-BIO-IRL-0130. Preparation Date: April 2021.